Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab versus placebo for MRD-positive stage II-III NSCLC after curative-intent therapy
jRCT2021200033Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab with Placebo (2 arms). Primary endpoint: Disease-free survival in PD-L1 tumor cell 1% or greater population. Started Dec 2020; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2021200033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021200033.